Advertisement

Les résultats de la chimiothérapie initiale des formes avancées des cancers épithéliaux de l’ovaire

  • I. Ray-Coquard
  • J.-P. Guastalla
Part of the Abord clinique book series (ONCOLPRAT)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Calvert AH, Newell DR, Gumbrell LA et al. (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7(11): 1748–56PubMedGoogle Scholar
  2. 2.
    Jelliffe RW (1973) Letter: Creatinine clearance: bedside estimate. Ann Intern Med 79(4): 604–5PubMedGoogle Scholar
  3. 3.
    Wright JG, Boddy AV, Highley M et al. (2001) Estimation of glomerular filtration rate in cancer patients. Br J Cancer 84(4): 452–9CrossRefPubMedGoogle Scholar
  4. 4.
    Martin L, Chatelut E, Boneu A et al. (1998) Improvement of the Cockcroft-Gault equation for predicting glomerular filtration in cancer patients. Bull Cancer 85(7): 631–6PubMedGoogle Scholar
  5. 5.
    Egorin MJ, Reyno LM, Canetta RM et al. (1994) Modeling toxicity and response in carboplatin-based combination chemotherapy. Semin Oncol 21(5 Suppl 12): 7–19PubMedGoogle Scholar
  6. 6.
    Poole SG, Dooley MJ, Rischin D (2002) A comparison of bedside renal function estimates and measured glomerular filtration rate (Tc99mDTPA clearance) in cancer patients. Ann Oncol 13(6): 949–55Google Scholar
  7. 7.
    Marx GM, Blake GM, Galani E et al. (2004) Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol 15(2): 291–5CrossRefPubMedGoogle Scholar
  8. 8.
    Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis (1991) The Ovarian Cancer Meta-Analysis Project. J Clin Oncol 9(9): 1668–74Google Scholar
  9. 9.
    A’Hern RP, Gore ME (1995) Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 13(3): 726–32PubMedGoogle Scholar
  10. 10.
    Colombo N, Bolis G, Danese S et al. (1995) Randomised comparison of two platinumbased high dose intensity (HDI) regimens in advanced ovarian carcinoma. Proc Am Soc Clin Oncol 14: 271Google Scholar
  11. 11.
    Hernadi Z, Juhasz B, Poka R et al. (1988) Randomised trial comparing combinations of cyclophosphamide and cisplatin without or with doxorubicin or 4′-epi-doxorubicin in the treatment of advanced ovarian cancer. Int J Gynaecol Obstet 27(2): 199–204CrossRefPubMedGoogle Scholar
  12. 12.
    Bezwoda WR (1986) Treatment of advanced ovarian cancer: a randomised trial comparing adriamycin or 4’epi-adriamycin in combination with cisplatin and cyclophosphamide. Med Pediatr Oncol 14(1): 26–9PubMedGoogle Scholar
  13. 13.
    Homesley HD, Harry DS, O’Toole RV et al. (1992) Randomized comparison of cisplatin plus epirubicin or doxorubicin for advanced epithelial ovarian carcinoma. a multicenter trial. Am J Clin Oncol 15(2): 129–34PubMedGoogle Scholar
  14. 14.
    Omura GA, Morrow CP, Blessing JA et al. (1983) A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma. Cancer 51(5): 783–9PubMedGoogle Scholar
  15. 15.
    Omura G, Blessing JA, Ehrlich CE et al. (1986) A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer 57(9): 1725–30PubMedGoogle Scholar
  16. 16.
    Omura GA, Bundy BN, Berek JS et al. (1989) Randomized trial of Cyclophosphamide plus Cisplatin with or without Doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 7: 457–65PubMedGoogle Scholar
  17. 17.
    Young RC, Chabner BA, Hubbard SP et al. (1978) Advanced ovarian adenocarcinoma: a prospective clinical trial of Melphalan (L-PAM) versus combination chemotherapy. N Engl J Med 299: 1261–6PubMedGoogle Scholar
  18. 18.
    Neijt JP, ten Bokkel H, van der Burg ME et al. (1984) Current status of systemic chemotherapy in the treatment of advanced ovarian cancer with emphasis on CHAP-5. Radiother Oncol 2(1): 19–29PubMedGoogle Scholar
  19. 19.
    Neijt JP, ten Bokkel H, van der Burg MEL et al. (1987) Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol 5: 1157–68PubMedGoogle Scholar
  20. 20.
    ICON2 (1998) Randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study [see comments] ANON1998. LancetGoogle Scholar
  21. 21.
    Buyse M, Burzykowski T, Parmar M et al. (2003) Using the expected survival to explain differences between the results of randomized trials: a case in advanced ovarian cancer. BUYSE2003. J Clin Oncol 21(9): 1682–7CrossRefPubMedGoogle Scholar
  22. 22.
    Levin L, Hryniuk WM (1987) Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 5(5): 756–67PubMedGoogle Scholar
  23. 23.
    Levin L, Simon R, Hryniuk W (1993) Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis. J Natl Cancer Inst 85[21], 1732–42PubMedGoogle Scholar
  24. 24.
    Jodrell DI, Egorin MJ, Canetta RM 1et al. (1992) Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10(4): 520–8PubMedGoogle Scholar
  25. 25.
    McGuire WP, Blessing JA, Moore D et al. (1996) Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study MCGUIRE1996. J Clin Oncol 14: 792–5PubMedGoogle Scholar
  26. 26.
    Piccart MJ, Bertelsen K, Stuart G et al. (2003) Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer 13Suppl 2: 144–8PubMedGoogle Scholar
  27. 27.
    Trimble EL, Adams JD, Vena D et al. (1993) Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 11(12): 2405–10PubMedGoogle Scholar
  28. 28.
    Ozols RF, Bundy BN, Greer BE et al. (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21(17): 3194–200CrossRefPubMedGoogle Scholar
  29. 29.
    Neijt JP, Engelholm SA, Tuxen MK et al. (2000) Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 18(17): 3084–92PubMedGoogle Scholar
  30. 30.
    du Bois A, Luck HJ, Meier W et al. (2003) A Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian Cancer. JNCI Cancer Spectrum 95(17): 1320–9Google Scholar
  31. 31.
    Vasey PA, Jayson GC, Gordon A et al. (2004) Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96(22): 1682–91PubMedGoogle Scholar
  32. 32.
    Kristensen GB, Vergote I, Stuart G et al. (2003) First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin. Int J Gynecol Cancer 13Suppl 2: 172–7: 172-7PubMedGoogle Scholar
  33. 33.
    Muggia FM, Braly PS, Brady MF et al. (2000) Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 18(1): 106–15PubMedGoogle Scholar
  34. 34.
    Sandercock J, Parmar MK, Torri V et al. (2002) First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence. Br J Cancer 87(8): 815–24CrossRefPubMedGoogle Scholar
  35. 35.
    Gershenson D, Follen M, Atkinson N et al. (1992) A decade of experience with cisplatinbased chemotherapy in patients with optimal epithelial ovarian cancer: ‘maintenance’ therapy reconsidered (meeting abstract). Society of Gynecologic Oncologists Twenty-third Annual Meeting March 15–8Google Scholar
  36. 36.
    Hakes T, Markman M, Lewis JL et al. (1992) Epithelial ovarian cancer (oc) in the elderly: the memorial sloan-kettering cancer center experience (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 11: A702Google Scholar
  37. 37.
    Bertelsen K, Jakobsen A, Stroyer J et al. (1993) A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). Gynecol Oncol 49(1): 30–6CrossRefPubMedGoogle Scholar
  38. 38.
    Lambert H, Rustin G, Nelstrop A et al. (1995) A randomised trial of 5 versus 8 courses of cisplatin or carboplatin in advanced ovarian carcinoma. (abstract 140). Fifth Biennial Meeting of the International Gynecologic Cancer Society, september 4–8, 1995, Philadelphia 5: 41Google Scholar
  39. 39.
    Neijt JP (1992) Treatment of advanced ovarian cancer: 10 years of experience. Ann Oncol 3(1): 17–27PubMedGoogle Scholar
  40. 40.
    Combination of markers may prove useful in screening for ovarian CA [news] (1994) Oncology (Huntingt) 8(6): 79–80Google Scholar
  41. 41.
    Scarfone G, Merisio C, Garavaglia E et al. (2002) A phase III trial of consolidation versus NIHIL (NIL) for advanced epithelial ovarian cancer (AEOC) after complete remission (CR). ASCO Proceedings [Abstract 812]Google Scholar
  42. 42.
    De Placido S, Scambia G, Di Vagno G et al. (2004) Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol 22(13): 2635–42PubMedGoogle Scholar
  43. 43.
    Pfisterer J, Lortholary A, Kimming R et al. (2003) Paclitaxel/carboplatin (TC) vs paclitaxel/ carboplatin followed by topotecan (TC-Top) in first-line treatment of ovarian cancer FIGO stages IIb-IV. Interim results of a gynecologic cancer intergroup phase III trial of the AGO Ovarian Cancer Study Group and GINECO. Proc Am Soc Clin Oncol 22: 446 (abstr 1793). 2005Google Scholar
  44. 44.
    Markman M, Liu PY, Wilczynski S et al. (2003) Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21(13): 2460–5CrossRefPubMedGoogle Scholar
  45. 45.
    Shimizu Y, Hasumi K (1993) [Treatment of stage III and IV ovarian cancer—is neoadjuvant chemotherapy effective?]. Nippon Sanka Fujinka Gakkai Zasshi 45(9): 1007–14PubMedGoogle Scholar
  46. 46.
    Lim JT, Green JA (1993) Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma. Clin Oncol (R Coll Radiol) 5(4): 198–202Google Scholar
  47. 47.
    Jacob JH, Gershenson DM, Morris M et al. (1991) Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol Oncol (42(2): 146–50CrossRefPubMedGoogle Scholar
  48. 48.
    Ng LW, Rubin SC, Hoskins WJ et al. (1990) Aggressive chemosurgical debulking in patients with advanced ovarian cancer. Gynecol Oncol (38(3): 358–63CrossRefPubMedGoogle Scholar
  49. 49.
    van der Burg ME, van Lent M, Buyse M et al. (1995) The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 332(10): 629–34PubMedGoogle Scholar
  50. 50.
    Rose PG, Nerenstone S, Brady MF et al. (2004) Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 351(24): 2489–97CrossRefPubMedGoogle Scholar
  51. 51.
    ICON1, EORTC ACTI (2003) International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm Trial: Two Parallel Randomized Phase III Trials of Adjuvant Chemotherapy in Patients With Early-Stage Ovarian Carcinoma. JNCI Cancer Spectrum 95(2): 105Google Scholar
  52. 52.
    Trimbos JB, Vergote I, Bolis G et al. (2003) Impact of Adjuvant Chemotherapy and Surgical Staging in Early-Stage Ovarian Carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm Trial. JNCI Cancer Spectrum 95(2): 113Google Scholar
  53. 53.
    Trimbos JB, Parmar M, Vergote I et al. (2003) International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 95(2): 105–12PubMedGoogle Scholar
  54. 54.
    Bolis G, Colombo N, Pecorelli S et al. (1995) Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica. Ann Oncol 6(9): 887–93PubMedGoogle Scholar
  55. 55.
    Trope C, Kaern J, Hogberg T et al. (2000) Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. Ann Oncol 11(3): 281–8PubMedGoogle Scholar

Copyright information

© Springer-Verlag France 2006

Authors and Affiliations

  • I. Ray-Coquard
  • J.-P. Guastalla

There are no affiliations available

Personalised recommendations